Second-Line Chemotherapy in Gastric Cancer: a Retrospective Study.

Area of Science:

• Oncology
• Medical Chemistry

Background:

• Second-line chemotherapy is crucial for patients with metastatic gastric cancer progressing after first-line treatment.
• Selecting the optimal regimen is essential for improving patient outcomes.

Purpose of the Study:

• To compare the efficacy of FOLFIRI, platinum-based, and taxane-based chemotherapy regimens as second-line treatment for metastatic gastric cancer.
• To determine the most appropriate second-line chemotherapy regimen based on overall survival and progression-free survival.

Main Methods:

• A study comparing three groups of HER-2 negative metastatic gastric cancer patients who received second-line chemotherapy.
• Inclusion criteria included disease progression after first-line chemotherapy and adequate organ function (ECOG score 0-2).
• Patients were assigned to FOLFIRI, platinum-based, or taxane-based regimens and compared for overall and progression-free survival.

Main Results:

• No statistically significant difference was observed in overall survival among the three groups (median OS: FOLFIRI 5 months, platinum-based 6.5 months, taxane-based 5.6 months; p=0.554).
• Progression-free survival also showed no significant difference between the regimens (median PFS: FOLFIRI 3.43 months, platinum-based 4 months, taxane-based 2.77 months; p=0.546).
• All three regimens demonstrated comparable efficacy in this patient population.

Conclusions:

• FOLFIRI, platinum-based, and taxane-based treatments are not statistically different in efficacy for second-line gastric cancer.
• Individual patient factors, including toxicity profiles and treatment costs, should guide the selection of second-line chemotherapy.